Clinical trials: Hepatic Neoplasm
Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma
The objective of this study is to evaluate the efficacy and safety of Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients in hepatocellular carcinoma.
- Trial name
- NCT03857815
- Testing
- anti-PD-1 antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Solid Tumours
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function; Part B will allow…
- Trial name
- NCT01894243
- Testing
- Olaparib tablet dosing
- Where
- 12 sites in Czechia, France and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery
In this study, the investigators will detect hepatocellular carcinoma lesions using fluoescence imaging with ITGA6 targeting probes during tumor resection surgery.
- Trial name
- NCT06204835
- Testing
- RD-Cy7 fluorophore
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Institute of Automation, Chinese Academy of Sciences
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic
Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic, Hepatocellular Carcinoma Non-Resectable
- Trial name
- NCT07861425
- Testing
- ACE723
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- Acepodia Biotech, Inc.
Hepatocellular Carcinoma
Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
For inoperable small hepatocellular carcinoma (HCC), stereotactic body radiotherapy (SBRT) is an effective and safe local treatment.
- Trial name
- HSBRT2402 (NCT06313190)
- Testing
- Stereotactic body radiotherapy, Sintilimab
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma (Icc)
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
The goal of this trial is to determine whether the combination of CISGEM and Rilvegostomig during the perioperative period works to improve outcomes of patient undergoing surgery of high-risk of intrahepatic cholangiocarcinoma
- Trial name
- PEHRICCA (NCT07128290)
- Testing
- CISGEM + Rilvegostomig
- Where
- 9 sites in France
- Volunteers
- 49 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Unresectable Hepatocellular Carcinoma
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned.
- Trial name
- STOP-HCC (NCT01556490)
- Testing
- TheraSphere
- Where
- 94 sites in United States, Belgium and 9 more
- Volunteers
- 526 people
- Sponsor
- Boston Scientific Corporation
Extrahepatic Bile Duct Cancer, Gastric Cancer
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer
- Trial name
- NCT00019474
- Testing
- filgrastim, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center
Hepatocellular Carcinoma
A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells
The aim of this study is to analyze the therapeutic effect of postoperative adjuvant chemotherapy with FOLFOX4 after hepatocarcinoma resection based on folate receptor-positive circulating tumor cells.
- Trial name
- NCT04521491
- Testing
- FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cancer, Radiofrequency Ablation
Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation
Percutaneous radiofrequency ablation is a commonly treatment for patients with liver cancer that cannot be surgically resected. During the procedure, patients need to keep awake and cooperate with the procedure, including deep…
- Conditions
- Liver Cancer, Radiofrequency Ablation, Esketamine, Dexmedetomidine
- Trial name
- NCT06003218
- Testing
- Dexmedetomidine-esketamine combination, Remifentanil, Oxycodone
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Peking University First Hospital
Gastric Cancer, Esophageal Cancer
PAN-study: Pan-Cancer Early Detection Study (PAN)
The PAN-cancer Early Detection study or PAN-study is a prospective cross-sectional observational case-control study evaluating whether Breath Biopsy can differentiate between patients with and without different cancer types by…
- Conditions
- Gastric Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- NCT03756597
- Testing
- ReCIVA, CASPER
- Where
- United Kingdom
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Owlstone Ltd
Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma
Systemic therapy is the primary option for managing advanced hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab (A+B) has emerged as the first-choice treatment for advanced HCC(IM brave 150).
- Trial name
- NCT06199297
- Testing
- Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma
When multi-kinase inhibitors based therapies (sorafenib and regorafenib) are limited in late-stage liver cancer patients, there is no alternative options.
- Trial name
- NCT03732547
- Testing
- PD-1 mAb, PolyIC
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma
Utility Study of Primovist-MRI on HCC Staging
Gadoxetic acid (Gd-EOB-DTPA, Primovist)-enhanced MRI can affect on BCLC staging during the initial staging workups of definite HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions…
- Trial name
- PrimovistMRI (NCT01764438)
- Testing
- Primovist-enhanced MRI
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Inha University Hospital
Cancer Colon, Cancer, Liver
Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
To evaluate the diagnostic performance of blood-based SPOT-MAS test in symptomatic individuals, the investigators sought to launch a prospective multicenter study, named K-ACCELERATE.
- Conditions
- Cancer Colon, Cancer, Liver, Cancer, Lung, Cancer, Breast
- Trial name
- K-ACCELERATE (NCT06391749)
- Where
- Vietnam
- Volunteers
- 1,000 people
- Sponsor
- Gene Solutions
Hepotacellular Carcinoma
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
This study is for patients with early-stage liver cancer who are planning to have surgery. The goal of this research is to see if a personalized treatment plan, guided by a computer model (an artificial intelligence tool), can…
- Trial name
- NCT07282184
- Testing
- Neoadjuvant HAIC + Lenvatinib + PD-1 Inhibitor, Curative Liver Resection, Multimodal AI Risk Stratification
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).
To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group' in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in China.
- Trial name
- HCC DC CTL (NCT02026362)
- Testing
- MASCT:Multiple Antigens Specific Cellular Therapy, The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- HRYZ Biotech Co.
Liver Cancer, Adult
NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC).
- Trial name
- NCT07295262
- Testing
- ICG-Cisplatin Nanoprobe (NIR-II NanoM), Fluorescence-guided Hepatectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma
Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
Compare the effect of liver transplantation (LT) plus ADV-TK gene therapy versus LT only in advanced primary hepatocellular carcinoma.
- Trial name
- NCT03313596
- Testing
- ADV-Tk, LT
- Where
- 11 sites in China
- Volunteers
- 180 people
- Sponsor
- Huazhong University of Science and Technology
Liver Cancer, Liver Failure
Quantitative MRI and Outcomes of Liver Resection
The present observational study aims to assess the benefit of this quantitative multiparametric magnetic resonance imaging (MRI) in clinical practice, to quantify future liver remnant performance, and to accurately predict the…
- Conditions
- Liver Cancer, Liver Failure, Bile Leak, Liver Metastases
- Trial name
- NCT06181318
- Testing
- Multiparametric MRI scan of the liver
- Volunteers
- 33 people
- Sponsor
- University Hospital Heidelberg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.